Bachem 2004 results with positive outlook for 2005
While margins were approximately maintained in local markets for the core peptide business, including peptide generics, non-peptide generics faced decreasing margins due to changes in product mix, investments in increased production capacity and price pressure for an important product. Results were further affected by the continued US dollar weakness. Accordingly, operating income was at CHF 42.2 million, down 8.4 percent (in local currencies) as compared to the previous reporting period. EBIT margin declined to 28.6 percent, and net income decreased by 13.4 percent compared to 2003 at CHF 32.3 million. Although the financial result was positive again at CHF 1.9 million, it could not fully compensate for increased expenditures of CHF 2.1 million on Pevion Biotech, the Bachem joint venture with Berna Biotech for the development of peptide-based vaccines.
Although economic development in Europe was lagging behind the US at the beginning of 2005, Bachem expects significant growth for the current year, with accelerating momentum during the second half of the year. A strong presence in the US and the start of commercialization of Symlin, the new anti-diabetic drug from Amylin Pharmaceuticals for which Bachem provides the active ingredient, as well as various other projects showing promising developments, indicate another substantial increase in market sales. Regulatory approvals are pending for four other products, while expanded production capabilities at Sochinaz and custom synthesis activities at the new center of excellence in the UK provide additional opportunities for broadening market penetration. Also, sales of an important product should recover, after de-stocking by a client ceased earlier than expected. Overall, Bachem forecasts double-digit sales growth for 2005, with over-proportional development of operational and net income.
Most read news
Organizations
Other news from the department business & finance
Get the chemical industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.